Top Page
HEALWELL AI
(TSX:AIDX)
HEALWELL AI (AIDX) vs. iShares MSCI Canada ETF (EWC)
HEALWELL AI Business Overview & Revenue Model
HEALWELL AI Earnings Call Summary
HEALWELL AI Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 100.17M | 38.97M | 7.32M | 10.42M | 47.82M | 38.57M |
| Gross Profit | 18.79M | 17.32M | 1.26M | 3.71M | 15.01M | 64.22M |
| EBITDA | -20.14M | -18.42M | -16.11M | -13.94M | -11.44M | 2.11M |
| Net Income | -59.22M | -26.29M | -31.60M | -21.09M | -15.67M | -1.03M |
Balance Sheet | ||||||
| Total Assets | 309.79M | 125.53M | 53.70M | 45.63M | 60.89M | 22.36M |
| Cash, Cash Equivalents and Short-Term Investments | 15.61M | 9.68M | 19.16M | 1.80M | 7.68M | 1.27M |
| Total Debt | 88.49M | 22.20M | 20.93M | 17.42M | 14.35M | 15.04M |
| Total Liabilities | 185.66M | 51.86M | 32.23M | 32.13M | 31.14M | 22.12M |
| Stockholders Equity | 120.31M | 63.89M | 12.65M | 11.78M | 28.03M | 114.00K |
Cash Flow | ||||||
| Free Cash Flow | -25.22M | -23.93M | -10.86M | -9.49M | -9.47M | 3.99M |
| Operating Cash Flow | -23.57M | -22.62M | -10.80M | -8.35M | -7.10M | 4.22M |
| Investing Cash Flow | -74.60M | -15.37M | 1.35M | -1.17M | -8.64M | -234.00K |
| Financing Cash Flow | 98.34M | 28.24M | 27.20M | 3.78M | 21.99M | -4.22M |
HEALWELL AI Technical Analysis
HEALWELL AI Peers Comparison
HEALWELL AI Corporate Events
HEALWELL AI issued additional disclosure at the request of the Ontario Securities Commission to clarify forward-looking information contained in its November 3, 2025 announcement of strategic divestments and business refocusing. The company explained that its referenced annual revenue run-rate of about $120 million and profitability on an Adjusted EBITDA basis are grounded principally in its Q3 2025 financial results, which showed $30.4 million in quarterly revenue from continuing operations—up 354% year over year—and a second consecutive quarter of positive Adjusted EBITDA following the acquisition of Orion Health. HEALWELL detailed the assumptions underpinning these projections, including sustained customer relationships, continued adoption of its software and AI tools, stable economic conditions, adequate financing, regulatory compliance amid evolving AI rules, respect of intellectual property, competitive dynamics, and its ability to keep innovating, underscoring the uncertainties and risks inherent in such forward-looking statements for investors and other stakeholders.
The most recent analyst rating on (TSE:AIDX) stock is a Buy with a C$2.50 price target. To see the full list of analyst forecasts on HEALWELL AI stock, see the TSE:AIDX Stock Forecast page.
HEALWELL AI has appointed Ian Kidson to its Board of Directors, bringing his extensive experience in financial, governance, and healthcare corporate leadership to the company. This strategic move is expected to bolster HEALWELL’s mission of advancing healthcare through early disease detection and improve its market positioning by leveraging Kidson’s expertise in guiding organizations through growth and transformation.
The most recent analyst rating on (TSE:AIDX) stock is a Hold with a C$0.94 price target. To see the full list of analyst forecasts on HEALWELL AI stock, see the TSE:AIDX Stock Forecast page.
HEALWELL AI Inc. reported a significant increase in revenue for Q3 2025, driven by the acquisition of Orion Health and strategic divestments that sharpen its focus on AI and SaaS healthcare solutions. The company achieved a 354% year-over-year revenue growth and marked its second consecutive quarter of positive Adjusted EBITDA, highlighting improved financial performance and execution of its growth strategy. HEALWELL’s full ownership of Pentavere Research Group and strategic collaborations in the Middle East are set to enhance its AI segment, positioning it as a leading player in the global healthcare market.
The most recent analyst rating on (TSE:AIDX) stock is a Buy with a C$5.00 price target. To see the full list of analyst forecasts on HEALWELL AI stock, see the TSE:AIDX Stock Forecast page.
HEALWELL AI has announced a series of strategic divestments and partnerships to focus on its core business of healthcare AI and SaaS services. The company has sold its Polyclinic Family Medicine and Specialty Group of Clinics to WELL Health Clinic Network Inc. and its interest in Mutuo Health Solutions Inc. to WELLSTAR Technologies Corp. Additionally, HEALWELL has formed a joint venture with WELL Health Technologies Corp. for clinical research. These transactions allow HEALWELL to streamline operations, enhance its focus on high-growth AI and software initiatives, and strengthen its financial position by adding approximately $9.4 million in cash.
The most recent analyst rating on (TSE:AIDX) stock is a Hold with a C$1.50 price target. To see the full list of analyst forecasts on HEALWELL AI stock, see the TSE:AIDX Stock Forecast page.
HEALWELL AI and its subsidiary Orion Health have signed a Memorandum of Understanding with Lean Business Services to explore the development and commercialization of AI-driven healthcare solutions in the Middle East and global markets. This collaboration aims to leverage HEALWELL’s AI capabilities, Orion Health’s interoperability expertise, and Lean’s market leadership in Saudi Arabia to improve population health outcomes and accelerate AI adoption in clinical workflows, aligning with Saudi Arabia’s Vision 2030 healthcare objectives.
The most recent analyst rating on (TSE:AIDX) stock is a Hold with a C$1.50 price target. To see the full list of analyst forecasts on HEALWELL AI stock, see the TSE:AIDX Stock Forecast page.
HEALWELL AI announced it will release its Fiscal Third Quarter 2025 financial results on November 6, 2025, followed by a conference call and webcast on November 7, 2025. This announcement is significant for stakeholders as it provides insights into the company’s financial health and operational progress, potentially impacting its market positioning and investor confidence.
The most recent analyst rating on (TSE:AIDX) stock is a Hold with a C$1.50 price target. To see the full list of analyst forecasts on HEALWELL AI stock, see the TSE:AIDX Stock Forecast page.
HEALWELL AI Inc. has filed an amended business acquisition report for its acquisition of Orion Health Holdings Limited, initially closed on April 1, 2025. The amendment updates the audit report to comply with International Standards on Auditing (ISA), replacing the previous compliance with ISA (New Zealand). This change was made following a review by the Ontario Securities Commission, ensuring the audit report aligns with ISA requirements and includes additional auditor responsibilities disclosure.
The most recent analyst rating on (TSE:AIDX) stock is a Buy with a C$3.80 price target. To see the full list of analyst forecasts on HEALWELL AI stock, see the TSE:AIDX Stock Forecast page.
HEALWELL AI recently completed a week-long series of business development and investor awareness activities in the UK, highlighting its AI-driven preventative healthcare solutions. The company engaged with prospective investors, partners, and acquisition targets, and hosted an exclusive event in London attended by healthcare leaders and financial institutions. The discussions emphasized the integration of AI into global healthcare systems, showcasing HEALWELL’s role as a key data science vendor for the UK NHS. The event reinforced the alignment between AI innovation and healthcare investment, and highlighted opportunities for HEALWELL to expand its presence in the UK market, leveraging its acquisition of Orion Health to accelerate growth.
The most recent analyst rating on (TSE:AIDX) stock is a Buy with a C$3.80 price target. To see the full list of analyst forecasts on HEALWELL AI stock, see the TSE:AIDX Stock Forecast page.
HEALWELL AI, in collaboration with Takeda Pharmaceutical, has demonstrated a groundbreaking use of its DARWEN™ AI platform to generate regulatory-grade real-world data on vedolizumab dose escalation for ulcerative colitis and Crohn’s disease. This achievement, presented at the United European Gastroenterology Week, highlights the platform’s potential to enhance patient outcomes and drive pharmaceutical advancements, further solidifying HEALWELL’s position as a leader in healthcare AI.
The most recent analyst rating on (TSE:AIDX) stock is a Hold with a C$1.50 price target. To see the full list of analyst forecasts on HEALWELL AI stock, see the TSE:AIDX Stock Forecast page.